Loperamide/simeticone 2 mg/125 mg caplets + Loperamide/simeticone 2 mg/125 mg chewable tablets + Probiotic Saccharomyces boulardii 250 mg capsules
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diarrhea
Conditions
Diarrhea
Trial Timeline
Nov 1, 2008 → Nov 1, 2009
NCT ID
NCT00807326About Loperamide/simeticone 2 mg/125 mg caplets + Loperamide/simeticone 2 mg/125 mg chewable tablets + Probiotic Saccharomyces boulardii 250 mg capsules
Loperamide/simeticone 2 mg/125 mg caplets + Loperamide/simeticone 2 mg/125 mg chewable tablets + Probiotic Saccharomyces boulardii 250 mg capsules is a approved stage product being developed by Johnson & Johnson for Diarrhea. The current trial status is completed. This product is registered under clinical trial identifier NCT00807326. Target conditions include Diarrhea.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00807326 | Approved | Completed |
Competing Products
20 competing products in Diarrhea